Internet Stroke Center Home Stroke Education for Clinicians & Students
 

Patients & Families   Health Professionals   Clinical Trials   About   Home 

 
 Stroke Education
Section Home
Neurology Core Curriculum

 Stroke Management
Emergency Treatment
Thrombolytic Case Management Series
CT Learning Tool
Anticoagulation is Acute Ischemic Stroke
Management of Intracerebral Hemorrhage
Emerging Therapies
Evaluation & Diagnosis
Stroke Care for EMT's & Paramedics
 Stroke Prevention
Antithrombotic Therapy & Stroke Prophylaxis
Can Statins Prevent the First Stroke?
Stroke Prevention in Atrial Fibrillation
Management of Oral Anticoagulant Therapy
 Brain Anatomy
Anatomy of the Brain
Blood Vessels of the Brain
Pathogenesis & Pathophysiology
 Brain Imaging
CT & MRI Criteria for Infarction & Hemorrhage
Guide to Imaging Techniques
MRI Compared to CT
 Stroke Facts
Epidemiology of Stroke
Stroke Risk Factors
Types of Stroke

 Search

Search the ISC 
Search the Web


Can Statins Prevent the First Stroke?

Is statins’ benefit mediated only through cholesterol reduction?

Meta-analysis of published trials strongly suggested that there may be a cholesterol independent effects.  Some of these effects include:

  • Improve endothelial cell function

  • Anti-inflammatory effect and antiplatelet effect

  • Anti-oxidant effect

  • Plaque stabilization

  • Antithrombotic effect


Which Statin to Use?

  • Only natural statins (simvastatin, pravastatin, and lovastatin) have been shown to prevent first and second MI and first ever stroke.

  • There is no direct evidence to support use of synthetic statins for prevention of MI and/or stroke.


Are Statins Interchangeable?

  • Statins were classified based on their ability to inhibit HMG CO A reductase.

  • There is no established clinical or scientific definition of class effect.

  • FDA defines a class as “all products within a class are assumed to be closely related in chemical structure, pharmacology, therapeutic activity, and adverse reactions”.

  • Differences have been shown in statins’ ability to inhibit cholesterol accumulation in macrophages.

  • Inhibition of SMC varies among the statins.

  • Lipophilic (not hydrophilic) statins suppress tissue factor expression, initiator of coagulation.

  • Lipophilic (not hydrophilic) statins were shown to impair recovery of myocardial cells after ischemia.

  • Atorvastatin has been shown to increase PAI-1 antigen level. It was also shown to increase fibrinogen and produce molecular changes in fibrinogen structure.

  • Atorvastatin at higher doses was shown to affect HDL unfavorably.

 

Back

Contents

Next

 

The content of these pages was written by Dr. Abdullah Nassief of Washington University School of Medicine, based on a presentation given in October of 2000.

Last Revised: October 31, 2000

 

 

This site is a non-profit, educational service of Washington University School of MedicineInternet Stroke Center at Washington University:
TOP | HOME | ABOUT | PRIVACY POLICY | CONTACT

Copyright © 1997-2003 - Internet Stroke Center. All rights reserved.

The information contained in this web site is not a substitute for medical advice or treatment.
Consultation with your doctor or health care professional is recommended.